Regeneron, Sanofi asthma drug data fails to excite investors

PARIS (Reuters) - Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor expectations.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Asthma | Health